News and Updates
iVeena closes Series B financing to advance multiple programs in clinical development and announces National Eye Institute SBIR Phase II Grant
iVeena, a clinical stage biopharmaceutical company with products in development for unmet needs in ophthalmology, announces the successful completion of the Series B preferred stock bridge round. The...
iVeena appoints Dr. Amir Shojaei to the iVeena Board of Directors. Dr. Shojaei was previously the Vice President and Therapeutic Area Head in Ophthalmology at Shire/Takeda.
Dr. Shojaei was the Vice President and Therapeutic Area (TA) Head in Ophthalmology at Shire/Takeda. He oversaw all aspects of clinical stage ophthalmic pipeline assets. Most recently, Amir's team brou...
iVeena announces the appointment of Dr. Jerry Hu, MD to the iVeena Scientific Advisory Board.
Dr. Hu is a leading private practitioner with a keen interest in academic and research endeavors. He is a partner and owner of Texas Eye and Laser Center, an internationally recognized center of excel...
iVeena announces the appointment of Dr. Vance Thompson, MD, to the iVeena Scientific Advisory Board.
Dr. Thompson is an internationally recognized specialist in Laser Vision Correction and Advanced Cataract Surgery. Vance Thompson, MD is an internationally recognized specialist in Laser Vision Corr...
iVeena announces the appointment of Robert Dempsey, Group Vice President and Head of the Global Ophthalmology Franchise at Takeda (formerly Shire) to the iVeena Board of Directors
iVeena announces the appointment of Robert Dempsey, Group Vice President and Head of the Global Ophthalmology Franchise at Takeda (formerly Shire) to the iVeena Board of Directors. “Mr. Dempsey will...
Page 3 of 9